Prednisone for Heart Failure Patients With Hyperuricemia
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 205 participants.
Also called NCT02129764
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 205 participants
- Sponsor
- Hebei Medical University
- Registry
-
NCT02129764
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02129764. Randomized; no masking; primary purpose treatment. Start 2013-12 (actual); primary completion 2018-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Prednisone for Heart Failure Patients With Hyperuricemia
- Acronym
- PUSH-PATH-2
- Condition
- Heart Failure, Hyperuricemia
- Intervention (Drug)
- Prednisone
- Intervention (Drug)
- Allopurinol
- Lead sponsor
- Hebei Medical University
Record details
- Record id
cardio:ct-nct02129764- Content hash
c8efbedaca763aacc564ec7c88e8f8de079114f071b93d719645c1213b407f0e